2024/09/19 更新

写真a

イシハラ シユンイチ
石原 俊一
ISHIHARA, Shunichi
所属
医学部附属病院 放射線科 病院教授
職名
病院教授

学位 1

  1. 医学博士 ( 2002年3月   名古屋大学 ) 

研究分野 2

  1. その他 / その他  / 放射線科学

  2. ライフサイエンス / 放射線科学

経歴 1

  1. 名古屋大学 医学部附属病院 放射線科   病院教授

学歴 2

  1. 名古屋大学   医学研究科

    1996年4月 - 2000年3月

      詳細を見る

    国名: 日本国

  2. 名古屋大学   医学部   医学科

    1988年4月 - 1994年3月

      詳細を見る

    国名: 日本国

所属学協会 7

  1. 日本医学放射線学会

  2. 日本放射線腫瘍学会   代議員

  3. 日本放射線腫瘍学会 高精度放射線外部照射部会

  4. 日本定位放射線治療学会

  5. 日本医学放射線学会

  6. 日本放射線腫瘍学会

  7. 日本頭頸部癌学会

▼全件表示

委員歴 1

  1. 日本放射線腫瘍学会   代議員  

      詳細を見る

    団体区分:学協会

    日本放射線腫瘍学会

受賞 1

  1. 優秀演題賞

    2011年11月   日本放射線腫瘍学会第24回学術大会   追跡調査精度と予後~非小細胞肺癌の場合~

    石原俊一、中原理絵、牧紗代、久保田誠司、岡田徹、伊藤善之、長縄慎二

     詳細を見る

    受賞区分:国内学会・会議・シンポジウム等の賞  受賞国:日本国

 

論文 43

  1. Evaluation of alterations in interstitial fluid dynamics in cases of whole-brain radiation using the diffusion-weighted image analysis along the perivascular space method 査読有り

    Taoka, T; Ito, R; Nakamichi, R; Nakane, T; Kawamura, M; Ishihara, S; Ichikawa, K; Kawai, H; Naganawa, S

    NMR IN BIOMEDICINE   37 巻 ( 7 ) 頁: e5030   2024年7月

     詳細を見る

    記述言語:英語   出版者・発行元:NMR in Biomedicine  

    In the current study, we assessed changes in interstitial fluid dynamics resulting after whole-brain radiotherapy using the diffusion-weighted image analysis along the perivascular space (DWI-ALPS) method, which is a simplified variation of the diffusion tensor image ALPS (DTI-ALPS) method using diffusion-weighted imaging (DWI) with orthogonal motion-probing gradients (MPGs). This retrospective study included 47 image sets from 22 patients who underwent whole-brain radiotherapy for brain tumors. The data for the normal control group comprised 105 image sets from 105 participants with no pathological changes. DWI was performed with the three MPGs applied in an orthogonal direction to the imaging plane, and apparent diffusion coefficient images for the x-, y-, and z-axes were retrospectively generated. The ALPS index was calculated to quantify interstitial fluid dynamics. The independent t-test was used to compare the ALPS index between normal controls and patients who underwent whole-brain radiotherapy. Patients were compared in all age groups and individual age groups (20–39, 40–59, and 60–84 years). We also examined the correlation between biologically equivalent doses (BEDs) and the ALPS index, as well as the correlation between white matter hyperintensity and the ALPS index. In the comparison of all age groups, the ALPS index was significantly lower (p < 0.001) in the postradiation group (1.32 ± 0.16) than in the control group (1.44 ± 0.17), suggesting that interstitial fluid dynamics were altered in patients following whole-brain radiotherapy. Significant age group differences were found (40–59 years: p < 0.01; 60–84 years: p < 0.001), along with a weak negative correlation between BEDs (r = −0.19) and significant correlations between white matter hyperintensity and the ALPS index (r = −0.46 for periventricular white matter, r = −0.38 for deep white matter). It was concluded that the ALPS method using DWI with orthogonal MPGs suggest alteration in interstitial fluid dynamics in patients after whole-brain radiotherapy. Further systematic prospective studies are required to investigate their association with cognitive symptoms.

    DOI: 10.1002/nbm.5030

    Web of Science

    Scopus

    PubMed

  2. The current state and future perspectives of radiotherapy for cervical cancer 査読有り

    Yamada, T; Kawamura, M; Oie, Y; Kozai, Y; Okumura, M; Nagai, N; Yanagi, Y; Nimura, K; Ishihara, S; Naganawa, S

    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH     2024年6月

     詳細を見る

    記述言語:英語   出版者・発行元:Journal of Obstetrics and Gynaecology Research  

    Radiotherapy is an effective treatment method for cervical cancer and is typically administered as external beam radiotherapy followed by intracavitary brachytherapy. In Japan, center shielding is used in external beam radiotherapy to shorten treatment time and reduce the doses delivered to the rectum or bladder. However, it has several challenges, such as uncertainties in calculating the cumulative dose. Recently, external beam radiotherapy has been increasingly performed with intensity-modulated radiotherapy, which reduces doses to the rectum or bladder without center shielding. In highly conformal radiotherapy, uncertainties in treatment delivery, such as inter-fractional anatomical structure movements, affect treatment outcomes; therefore, image-guided radiotherapy is essential for appropriate and safe performance. Regarding intracavitary brachytherapy, the use of magnetic resonance imaging-based image-guided adaptive brachytherapy is becoming increasingly widespread because it allows dose escalation to the tumor and accurately evaluates the dose delivered to the surrounding normal organs. According to current evidence, a minimal dose of D90% of the high-risk clinical target volume is significantly relevant to local control. Further improvements in target coverage have been achieved with combined interstitial and intracavity brachytherapy for massive tumors with extensive parametrical involvement. Introducing artificial intelligence will enable faster and more accurate generation of brachytherapy plans. Charged-particle therapies have biological and dosimetric advantages, and current evidence has proven their effectiveness and safety in cervical cancer treatment. Recently, radiotherapy-related technologies have advanced dramatically. This review provides an overview of technological innovations and future perspectives in radiotherapy for cervical cancer.

    DOI: 10.1111/jog.15998

    Web of Science

    Scopus

    PubMed

  3. Palliative radiotherapy for painful non-bone lesions in patients with advanced cancer: a single center retrospective study 査読有り

    Shindo, Y; Koide, Y; Nagai, N; Kitagawa, T; Aoyama, T; Shimizu, H; Hashimoto, S; Tachibana, H; Kodaira, T; Ishihara, S; Naganawa, S

    JAPANESE JOURNAL OF RADIOLOGY   42 巻 ( 6 ) 頁: 656 - 661   2024年6月

     詳細を見る

    記述言語:英語   出版者・発行元:Japanese Journal of Radiology  

    Purpose: This retrospective study aimed to assess the efficacy and safety of palliative radiotherapy for painful non-bone lesions in patients with advanced cancer. Materials and methods: We enrolled patients with painful non-bone lesions who underwent conventional palliative radiotherapy between September 2018 and September 2022. The treatment targets included primary tumor lesions, lymph node metastases, non-bone hematogenous metastases, and other lesions. The primary endpoint was the overall pain response rate in evaluable patients, determined based on the International Consensus Pain Response Endpoint criteria. The secondary endpoints included overall survival, pain recurrence, and adverse events. Results: Of the 420 screened patients, 142 received palliative radiotherapy for painful non-bone lesions, and 112 were evaluable. A pain response was achieved in 67 patients (60%) of the 112 evaluable patients within a median of 1.2 months. Among these patients, 25 exhibited complete response, 42 partial response, 18 indeterminate response, and 27 pain progression. The median survival time was 5.5 months, recorded at a median follow-up of 6.0 months, during which 67 patients died. Multivariate analysis identified poor performance status scores of 2–4, opioid use, and re-irradiation as independent factors associated with a reduced likelihood of achieving a pain response. Pain recurrence occurred in 18 patients over a median of 4.1 months. Seventeen patients had grade 1–2 adverse events, while none experienced grade 3 or higher toxicity. Conclusion: Palliative radiotherapy can potentially be a safe and well-tolerated modality for managing painful non-bone lesions, with a low rate of adverse events.

    DOI: 10.1007/s11604-024-01536-0

    Web of Science

    Scopus

    PubMed

  4. Reirradiation for recurrent gynecologic cancer using high-dose-rate brachytherapy in Japan: A multicenter survey on practice patterns and outcomes 査読有り

    Isohashi, F; Yoshida, K; Murakami, N; Masui, K; Ishihara, S; Ohkubo, Y; Kaneyasu, Y; Kinoshita, R; Kotsuma, T; Takaoka, Y; Tanaka, E; Nagao, A; Ogawa, K; Yamazaki, H

    RADIOTHERAPY AND ONCOLOGY   195 巻   頁: 110269   2024年6月

     詳細を見る

    記述言語:英語   出版者・発行元:Radiotherapy and Oncology  

    Background and purpose: The aim of the study is to examine the present status of reirradiation with high-dose-rate (HDR) brachytherapy for recurrent gynecologic cancer in Japan and to determine the role of this therapy in clinical practice. Materials and methods: A retrospective multicenter chart review was performed for reirradiation for gynecologic cancer using HDR brachytherapy. Each center provided information on patient characteristics, treatment outcomes, and complications. Results: The study included 165 patients treated at 9 facilities from 2000 to 2018. The analysis of outcomes included 142 patients treated with curative intent. The median follow-up time for survivors was 30 months (range 1–130 months). The 3-year overall survival (OS), progression-free survival (PFS), and local control (LC) rates were 53 % (95 %CI: 42–63 %), 44 % (35–53 %), and 61 % (50–70 %) for cervical cancer; 100 % (NA), 64 % (30–85 %), and 70 % (32–89 %) for endometrial cancer; and 54 % (13–83 %), 38 % (6–72 %), and 43 % (6–78 %) for vulvar and vaginal cancer, respectively. In multivariate analysis, interval to reirradiation (<1 year) was a significant risk factor for OS, PFS and LC; Gross Tumor Volume (≥25 cm3) was a significant risk factor for OS. Toxicities were analyzed in all enrolled patients (n = 165). Grade ≥ 3 late toxicities occurred in 49 patients (30 %). A higher cumulative EQD2 (α/β = 3) was significantly associated with severe complications. Conclusion: Reirradiation with HDR brachytherapy for recurrent gynecologic cancer is effective, especially in cases with a long interval before reirradiation.

    DOI: 10.1016/j.radonc.2024.110269

    Web of Science

    Scopus

    PubMed

  5. Stereotactic radiotherapy for ventricular tachycardia: A study protocol 査読有り

    Kawamura M., Shimojo M., Inden Y., Kamomae T., Okudaira K., Komada T., Aoki S., Shindo Y., Yasui R., Yanagi Y., Okumura M., Yamada T., Kozai Y., Oie Y., Kato Y., Ishihara S., Murohara T., Naganawa S.

    F1000Research   12 巻   頁: 798   2023年12月

     詳細を見る

    記述言語:英語   出版者・発行元:F1000Research  

    Background: Currently, the standard curative treatment for ventricular tachycardia (VT) and ventricular fibrillation (VF) is radiofrequency catheter ablation. However, when the VT circuit is deep in the myocardium, the catheter may not be delivered, and a new, minimally invasive treatment using different energies is desired. Methods: This is a protocol paper for a feasibility study designed to provide stereotactic radiotherapy for refractory VT not cured by catheter ablation after at least one catheter ablation. The primary end point is to evaluate the short-term safety of this treatment and the secondary endpoint is to evaluate its efficacy as assessed by the reduction in VT episode. Cyberknife M6 radiosurgery system will be used for treatment, and the prescribed dose to the target will be 25Gy in one fraction. The study will be conducted on three patients. Conclusion: Since catheter ablation is the only treatment option for VT that is covered by insurance in Japan, there is currently no other treatment for VT/VF that cannot be cured by catheter ablation. We hope that this feasibility study will provide hope for patients who are currently under the stress of ICD activation. Trial registration: The study has been registered in the Japan Registry of Clinical Trials (jRCTs042230030).

    DOI: 10.12688/f1000research.138758.2

    Scopus

    PubMed

  6. Shifting-field-of-view technique enhancing the inflow effect for identifying tumor/vessel boundaries in MRI for radiotherapy treatment planning 査読有り

    Kato, Y; Okudaira, K; Noguchi, Y; Kawamura, M; Ishihara, S; Naganawa, S

    RADIOLOGICAL PHYSICS AND TECHNOLOGY   16 巻 ( 4 ) 頁: 578 - 583   2023年12月

     詳細を見る

    記述言語:英語   出版者・発行元:Radiological Physics and Technology  

    This study presents two cases of tumors in contact with the inferior vena cava during radiotherapy, and introduces a clinically useful technique for identifying tumor boundaries adjacent to blood vessels by adjusting the position of the field-of-view (FOV) to enhance the inflow effect in magnetic resonance imaging. We named this technique “Shifting-FOV.” This method consists of three steps: (1) remove the upper and lower saturation pulses outside the FOV, (2) align the FOV to position the lower edge of the imaging slab as close to the tumor as possible, and (3) manually adjust the table position to locate the tumor at the center of the magnetic field. The proposed method allowed for accurate identification of the tumor/vessel boundaries in both cases. This is a useful technique that can be readily applied to other facilities. Furthermore, images obtained using this technique may enable accurate tumor contouring in radiotherapy treatment planning.

    DOI: 10.1007/s12194-023-00745-y

    Web of Science

    Scopus

    PubMed

  7. Urethral identification using three-dimensional magnetic resonance imaging and interfraction urethral motion evaluation for prostate stereotactic body radiotherapy 査読有り

    Kato, Y; Okumiya, S; Okudaira, K; Ito, J; Kumagai, M; Kamomae, T; Noguchi, Y; Kawamura, M; Ishihara, S; Naganawa, S

    NAGOYA JOURNAL OF MEDICAL SCIENCE   85 巻 ( 3 ) 頁: 504 - 517   2023年8月

     詳細を見る

    記述言語:英語   出版者・発行元:Nagoya Journal of Medical Science  

    Prostatic urethra identification is crucial in prostate stereotactic body radiotherapy (SBRT) to reduce the risk of urinary toxicity. Although computed tomography (CT) with a catheter is commonly employed, it is invasive, and catheter placement may displace the urethral position, resulting in possible planning inaccuracies. However, magnetic resonance imaging (MRI) can overcome these weaknesses. Accurate urethral identification and minimal daily variation could ensure a highly accurate SBRT. In this study, we investigated the usefulness of a three-dimensional (3D) T2-weighted (T2W) sequence for urethral identification, and the interfractional motion of the prostatic urethra on CT with a catheter and MRI without a catheter for implementing noninvasive SBRT. Thirty-two patients were divided into three groups. The first group underwent MRI without a catheter to evaluate urethral identification by two-dimensional (2D)- and 3D-T2W sequences using mean slice-wise Hausdorff distance (MSHD) and Dice similarity coefficient (DSC) of the contouring by two operators and using visual assessment. The second group provided 3-day MRI data without a catheter using 3D-T2W, and the third provided 3-day CT data with a catheter to evaluate the interfractional motion using MSHD, DSC, and displacement distance (Dd). The MSHD and DSC for the interoperator variability in urethral identification and visual assessment were superior in 3D-T2W than in 2D-T2W. Regarding interfractional motion, the Dd value for prostatic urethra was smaller in MRI than in CT. These findings indicate that the 3D-T2W yielded adequate prostatic urethral identification, and catheter-free MRI resulted in less interfractional motion, suggesting that 3D-T2W MRI without a catheter is a feasible noninvasive approach to performing prostate SBRT.

    DOI: 10.18999/nagjms.85.3.504

    Web of Science

    Scopus

    PubMed

  8. Prognostic impact of <i>EGFR</i>/<i>ALK</i> alterations in leptomeningeal metastasis from lung adenocarcinoma treated with whole-brain radiotherapy 査読有り

    Oyoshi, H; Hirata, H; Hirano, Y; Zenda, S; Zhou, YZ; Tomizawa, K; Fujisawa, T; Nakamura, M; Hojo, H; Motegi, A; Kageyama, SI; Zenke, Y; Goto, K; Ishihara, S; Naganawa, S; Akimoto, T

    CLINICAL & EXPERIMENTAL METASTASIS   40 巻 ( 5 ) 頁: 407 - 413   2023年7月

     詳細を見る

    記述言語:英語   出版者・発行元:Clinical and Experimental Metastasis  

    The prognosis and prognostic factors of patients receiving whole-brain radiotherapy (WBRT) for leptomeningeal metastasis (LM) from lung adenocarcinoma have not been established. Particularly, the impact of EGFR mutations and ALK rearrangements on survival remains unclear. This retrospective study evaluated the prognosis and prognostic factors of patients receiving WBRT for LM. We evaluated overall survival (OS) from WBRT initiation and clinical variables in 80 consecutive patients receiving WBRT for LM from lung adenocarcinoma at our institution between June 2013 and June 2021. After a median follow-up of 5.2 (range 0.5–56.5) months, the median OS was 6.2 months (95% CI 4.4–12.4). Of the 80 patients, 51 were classified as EGFR/ALK mutant (EGFR: 44; ALK: 6; both: 1) and 29 as wild-type. The median OS was 10.4 (95% CI 5.9–20.9) versus 3.8 (95% CI 2.5–7.7) months in the EGFR/ALK-mutant versus wild-type patients (HR = 0.49, P = 0.0063). Multivariate analysis indicated that EGFR/ALK alterations (HR = 0.54, P = 0.021) and Eastern Cooperative Oncology Group performance status (ECOG PS) of 0–1 (HR = 0.25, P < 0.001) were independent factors associated with favorable OS. Among the patients who underwent brain MRI before and after WBRT, intracranial progression-free survival was longer in the 26 EGFR/ALK-mutant than 13 wild-type patients (HR = 0.31, P = 0.0039). Although the prognosis of patients receiving WBRT for LM remains poor, EGFR/ALK alterations and good ECOG PS may positively impact OS in those eligible for WBRT.

    DOI: 10.1007/s10585-023-10225-7

    Web of Science

    Scopus

    PubMed

  9. Retrospective non-inferiority study of stereotactic radiosurgery for more than ten brain metastases 査読有り

    Nagai, N; Koide, Y; Shindo, Y; Hashimoto, S; Tachibana, H; Kodaira, T; Ishihara, S; Naganawa, S

    JOURNAL OF NEURO-ONCOLOGY   163 巻 ( 2 ) 頁: 385 - 395   2023年6月

     詳細を見る

    記述言語:英語   出版者・発行元:Journal of Neuro-Oncology  

    Aim: This study aimed to investigate the clinical benefits of stereotactic radiosurgery (SRS) in patients with > 10 brain metastases (BM) compared to patients with 2–10 BM. Methods: The study included multiple BM patients who underwent SRS between 2014 and 2022, excluding patients who underwent whole brain radiotherapy, had a Karnofsky Performance Status score < 60, suspected leptomeningeal disease, or a single BM lesion. Patients were divided into two groups (2–10 and > 10 BM groups) and matched 2:1 based on propensity scores. The primary endpoint was overall survival (OS) in the matched dataset, with intracranial progression-free survival (PFS) as the secondary endpoint. Non-inferiority was established if the upper limit of the 95% confidence interval (CI) of the adjusted hazard ratio was below 1.3. Results: Of the 1042 patients identified, 434 met eligibility criteria. After propensity score matching, 240 patients were analyzed (160 in the BM 2–10 group and 80 in the > 10 BM group). The median OS was 18.2 months in the 2–10 BM group and 19.4 months in the > 10 BM group (P = 0.60). The adjusted hazard ratio was 0.86 (95% CI: 0.59–1.24), indicating non-inferiority. PFS was not significantly different between the groups (4.8 months vs. 4.8 months, P = 0.94). The number of BM did not significantly impact OS or PFS. Conclusions: SRS for selected patients with > 10 BM was non-inferior in terms of OS compared to those with 2–10 BM in a propensity score-matched dataset.

    DOI: 10.1007/s11060-023-04358-8

    Web of Science

    Scopus

    PubMed

  10. Optimized radiotherapy treatment strategy for early glottic carcinoma 査読有り

    Ono, T; Itoh, Y; Ishihara, S; Kawamura, M; Oie, Y; Takase, Y; Okumura, M; Oyoshi, H; Nagai, N; Naganawa, S

    NAGOYA JOURNAL OF MEDICAL SCIENCE   85 巻 ( 2 ) 頁: 241 - 254   2023年5月

     詳細を見る

    記述言語:英語   出版者・発行元:Nagoya Journal of Medical Science  

    The local control rates of T1 bulky and T2 glottic carcinoma treated via radiation therapy alone are unsatisfactory; thus, we aimed to evaluate the efficacy and safety of our treatment protocol for early glottic carcinoma. Patients with early glottic squamous cell carcinoma treated via radiation therapy from January 2007 to November 2019 were reviewed. Patients were treated with: 63–67.5 Gy/28–30 fractions of radiation therapy alone for T1 non-bulky; concurrent chemoradiotherapy with S-1 and 60 Gy/30 fractions for T1 bulky and T2 favorable; and concurrent chemoradiotherapy with high-dose cisplatin and 66–70 Gy/33–35 fractions for T2 unfavorable glottic carcinoma. Local failure rates were estimated using the cumulative incidence function, overall and disease specific survival rates were estimated using Kaplan-Meier analysis, and adverse events were evaluated. Eighty patients were analyzed; the median age was 69.5 (range, 26–90) years, the median follow-up time for survivors was 40.1 (range, 1.9–128.4) months, and the 3-year local failure, disease specific survival, and overall survival rates were 5.8%, 98.3%, and 94.4%, respectively. In T1 bulky and T2 cases, the local failure rate was significantly lower in the concurrent chemoradiotherapy than in the radiation therapy alone group. Grade 3 acute dermatitis and mucositis were noted in nine and four patients, respectively. There were no acute adverse events of Grade 4 or higher, or late adverse events of Grade 2 or higher. The treatment protocol was effective and well-tolerated; thus, the efficacy of concurrent chemoradiotherapy was suggested in T1 bulky and T2 cases

    DOI: 10.18999/nagjms.85.2.241

    Web of Science

    Scopus

    PubMed

  11. retrospective study of cervical cancer with radiation dose reduction in concurrent chemoradiotherapy 査読有り

    Nagai, N; Kawamura, M; Ishihara, S; Oie, Y; Kozai, Y; Takase, Y; Okumura, M; Shindo, Y; Yasui, R; Yanagi, Y; Naganawa, S

    RADIOTHERAPY AND ONCOLOGY   182 巻   頁: S1921 - S1922   2023年5月

     詳細を見る

  12. Feasibility assessment of global standard chemoradiotherapy followed by surgery in patients with esophageal cancer 査読有り

    Liang, Y; Maeda, O; Miyata, K; Kanda, M; Shimizu, D; Sugita, S; Okada, T; Ito, J; Kawamura, M; Ishihara, S; Nakatochi, M; Ando, M; Kodera, Y; Ando, Y

    MOLECULAR AND CLINICAL ONCOLOGY   18 巻 ( 4 ) 頁: 34   2023年4月

     詳細を見る

    記述言語:英語   出版者・発行元:Molecular and Clinical Oncology  

    The present study aimed to assess the feasibility of global standard chemoradiotherapy (CRT) followed by surgery in patients with esophageal cancer. A prospective study was conducted at Nagoya University Hospital (Nagoya, Japan) to evaluate global standard CRT followed by surgery in patients with esophageal cancer. The CRT regimen consisted of 75 mg/m2 cisplatin on day 1 and 1,000 mg/m2 fluorouracil daily on days 1-4 given twice 4 weeks apart together with concurrent esophageal irradiation starting on day 1 (group A). For comparison, 17 patients with esophageal cancer who had received the same chemotherapy regimen but with lower drug doses were retrospectively reviewed: 70 mg/m2 cisplatin on day 1 and 700 mg/m2 fluorouracil daily on days 1-4 given twice 4 weeks apart together with concurrent esophageal irradiation starting on day 1 (group B). Grade 3 or worse adverse events were observed in 9 of the 12 patients (75%) in group A and in 5 of the 17 patients (29%) in group B. The patients in group A were more likely to experience grade 3 or worse neutropenia (50%) than those in group B (6%). No febrile neutropenia or treatment-related deaths occurred in either group. A total of 11 patients (92%) in group A and 16 patients (94%) in group B subsequently underwent an esophagectomy, and 9 (82%) and 14 (88%) of these patients, respectively, achieved microscopically margin-negative resection (R0 resection). In conclusion, global standard CRT was more likely to cause severe but manageable adverse events. There was no apparent difference in the R0 resection rate or postoperative complications between the two treatments. This clinical trial was registered at the Japan Registry of Clinical Trials (trial registration number: jRCT1041180004) on September 11, 2018.

    DOI: 10.3892/mco.2023.2630

    Web of Science

    Scopus

    PubMed

  13. Iodinated Contrast Media Substitution to Prevent Recurrent Hypersensitivity Reactions: A Systematic Review and Meta-Analysis

    Umakoshi, H; Nihashi, T; Takada, A; Hirasawa, N; Ishihara, S; Takehara, Y; Naganawa, S; Davenport, MS; Terasawa, T

    RADIOLOGY   305 巻 ( 2 ) 頁: 341 - 349   2022年11月

     詳細を見る

    記述言語:英語   出版者・発行元:Radiology  

    Background: Changing iodinated contrast media (ICM) may reduce the risk of recurrent ICM-induced hypersensitivity reactions in patients with a prior reaction. Purpose: To perform a systematic review on the effectiveness of ICM change in comparison with no change to prevent recurrent ICM immediate hypersensitivity reactions. Materials and Methods: Multiple data bases were searched without language restriction between January 1990 and August 2021 to identify comparative studies of any design that included patients with a prior ICM hypersensitivity reaction to low-osmolality ICM and re-exposure to intravascular ICM. The methods used included a duplicate assessment of eligibility, double extraction of quantitative data, validity assessment, and random-effects meta-analysis. The primary outcome was the incidence of all-grade immediate recurrent hypersensitivity reactions. Secondary outcomes were the incidence of severe immediate recurrent hypersensitivity reactions and other adverse events associated with ICM change. Results: Six retrospective observational studies at moderate to severe risk of bias assessed 7155 adult patients (4329 in the ICM change group and 2826 in the no-change group). Studies adopted nonstandardized switching methods, and the proportions of the ICM change group ranged between 19% (five of 27 examinations) and 80% (3104 of 3880 examinations). A Bayesian meta-analysis revealed that changing ICM was associated with a reduced risk of recurrent hypersensitivity reaction by 61% (risk ratio = 0.39; 95% credible interval [CrI]: 0.24, 0.58). The wide-ranging estimates of risk reduction were not explained by the risk of bias ratings, the event rates in the no-change group, the index-reaction severity, or the co-administered nonstandard premedication. Rare severe recurrent reactions (five studies with five events) precluded a conclusion (risk ratio = 0.34, favoring ICM change; CrI: 0.01, 3.74). Adverse events associated with ICM change were not reported. Conclusion: In observational evidence of limited quality, iodinated contrast media (ICM)–change was associated with a reduced risk of recurrent immediate hypersensitivity reaction in patients with a prior ICM-induced hypersensitivity reaction.

    DOI: 10.1148/radiol.220370

    Web of Science

    Scopus

    PubMed

  14. Development of a high-resolution two-dimensional detector-based dose verification system for tumor-tracking irradiation in the CyberKnife system

    Kawabata, F; Kamomae, T; Okudaira, K; Komori, M; Oguchi, H; Sasaki, M; Mori, M; Kawamura, M; Abe, S; Ishihara, S; Naganawa, S

    JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS   23 巻 ( 8 ) 頁: e13645   2022年8月

     詳細を見る

    記述言語:英語   出版者・発行元:Journal of Applied Clinical Medical Physics  

    We aim to evaluate the basic characteristics of SRS MapCHECK (SRSMC) for CyberKnife (CK) and establish a dose verification system using SRSMC for the tumor-tracking irradiation for CK. The field size and angular dependence of SRSMC were evaluated for basic characterization. The output factors (OPFs) and absolute doses measured by SRSMC were compared with those measured using microDiamond and microchamber detectors and those calculated by the treatment planning system (TPS). The angular dependence was evaluated by comparing the SRSMC with a microchamber. The tumor-tracking dose verification system consists of SRSMC and a moving platform. The doses measured using SRSMC were compared with the doses measured using a microchamber and radiochromic film. The OPFs and absolute doses of SRSMC were within ±3.0% error for almost all field sizes, and the angular dependence was within ±2.0% for all incidence angles. The absolute dose errors between SRSMC and TPS tended to increase when the field size was smaller than 10 mm. The absolute doses of the tumor-tracking irradiation measured using SRSMC and those measured using a microchamber agreed within 1.0%, and the gamma pass rates of SRSMC in comparison with those of the radiochromic film were greater than 95%. The basic characteristics of SRSMC for CK presented acceptable results for clinical use. The results of the tumor-tracking dose verification system realized using SRSMC were equivalent to those of conventional methods, and this system is expected to contribute toward improving the efficiency of quality control in many facilities.

    DOI: 10.1002/acm2.13645

    Web of Science

    Scopus

    PubMed

  15. The Incidence and Its Associated Factors Relevant to Brain Radionecrosis That Requires Intervention Following Single or Fractionated Stereotactic Radiosurgery Using Vero4DRT for Brain Metastases

    Yamada, T; Ohtakara, K; Kamomae, T; Itoh, J; Shimada, H; Ishihara, S; Naganawa, S

    CUREUS JOURNAL OF MEDICAL SCIENCE   14 巻 ( 6 ) 頁: e25888   2022年6月

     詳細を見る

  16. A Retrospective Analysis of R-MPV Plus Response-adapted Whole-brain Radiotherapy for Elderly Patients with Primary Central Nervous System Lymphoma

    Suzuki, Y; Imoto, N; Ishihara, S; Fujiwara, S; Ito, R; Sakai, T; Yamamoto, S; Sugiura, I; Kurahashi, S

    INTERNAL MEDICINE   61 巻 ( 9 ) 頁: 1345 - 1352   2022年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:一般社団法人 日本内科学会  

    Objective Few reports have described the real-world outcomes of rituximab, methotrexate (MTX), procarbazine, and vincristine (R-MPV) plus response-adapted whole-brain radiotherapy (WBRT) for elderly patients with primary central nervous system lymphoma (PCNSL). We evaluated the outcome of this regimen. Methods We evaluated >60-year-old patients with newly diagnosed PCNSL who received R-MPV plus WBRT from January 2010 to December 2019 at Toyohashi Municipal Hospital. The patients' characteristics, regimen enforcement, response rate, survival, and toxicity were analyzed. Patients Ten patients were consecutively enrolled. Their median age was 69 years old, and 60% had a performance status of 3 or 4 before induction therapy. Results Seven patients achieved a complete response after induction, and all 10 patients achieved a complete response after consolidation. Seven received reduced-dose WBRT at 23.4 Gy, and 2 received WBRT at 45 Gy. The median follow-up was 44.4 months; the 3-year progression-free survival and overall survival rates were 60% and 80%, respectively; and the cumulative incidence of relapse was 40%. The incidence of symptomatic delayed neurotoxicity was 70%. Of the 7 patients who received reduced-dose WBRT, 4 (57%) developed delayed neurotoxicity, including 1 severely affected patient. Only one patient survived without relapse and delayed neurotoxicity. The ratio of patients who developed relapse or delayed neurotoxicity that impaired daily life was 33% and 100% in the MTX high- and low-intensity groups, respectively. Conclusion This regimen in elderly patients is unsatisfactory because of delayed neurotoxicity. We should consider maintaining an adequate MTX intensity, postponing or minimizing WBRT, and choosing high-dose consolidation therapy for select patients.

    DOI: 10.2169/internalmedicine.7805-21

    Web of Science

    Scopus

    PubMed

    CiNii Research

  17. Poor local control of ulcerative T1 glottic cancer treated with 2.25-Gy per fraction radiotherapy 査読有り

    Oie, Y; Itoh, Y; Kawamura, M; Takase, Y; Murao, T; Ishihara, S; Nomoto, Y; Hirasawa, N; Asano, A; Yamakawa, K; Ito, J; Kinoshita, F; Naganawa, S

    NAGOYA JOURNAL OF MEDICAL SCIENCE   83 巻 ( 4 ) 頁: 811 - 825   2021年11月

     詳細を見る

    記述言語:英語   出版者・発行元:Nagoya Journal of Medical Science  

    The Tokai Study Group for Therapeutic Radiology and Oncology (TOSTRO) started managing T1 glottic cancer using 2.25 Gy/fraction radiotherapy in 2011. The aim was to evaluate the local control (LC) rate and toxicity with 2.25-Gy radiotherapy in clinical practice and identify prognostic factors.The eligibility criteria were T1 glottic squamous cell carcinoma patients with age ≥20 years, treated with 2.25 Gy/fraction without chemotherapy between 2011 and 2017. LC rates were evaluated based on age, performance status, sex, T-category, tumor type (ulcerative or non-ulcerative), presence of anterior commissure invasion, tumor size, X-ray beam energy, and overall treatment time. Acute and late adverse events were evaluated using CTCAE version 4.0. A total of 202 patients were enrolled. The median follow-up period was 34.2 months. The 2 and 4-year LC rates were 93.8% and 93.1%, respectively. There was a significant difference in the LC rate between non-ulcerative type and ulcerative type (95.2% vs. 74.1% at 2 years, 94.4% vs. 74.1% at 4 years; p = 0.01). On univariate analysis, only tumor type was significantly correlated with a poor LC rate (hazard ratio 4.3; 95% confidence interval 1.2–15.4; p = 0.03). Acute grade 3 adverse events occurred in 17 patients. However, no late adverse events of grade 3 or higher have occurred to date. T1 glottic cancer treatment outcomes using hypofractionated radiotherapy with 2.25 Gy/fraction in clinical practice were comparable to previously reported results. However, ulcerative type tumor was associated with a poor LC rate.

    DOI: 10.18999/nagjms.83.4.811

    Web of Science

    Scopus

    PubMed

  18. The importance of choosing the right strategy to treat small cell carcinoma of the cervix: a comparative analysis of treatments 査読有り

    Kawamura, M; Koide, Y; Murai, T; Ishihara, S; Takase, Y; Murao, T; Okazaki, D; Yamaguchi, T; Uchiyama, K; Itoh, Y; Kodaira, T; Shibamoto, Y; Mizuno, M; Kikkawa, F; Naganawa, S

    BMC CANCER   21 巻 ( 1 ) 頁: 1046   2021年9月

     詳細を見る

    記述言語:英語   出版者・発行元:BMC Cancer  

    Background: Standard treatments for small cell carcinoma of the cervix (SCCC) have not been established. In this study, we aimed to estimate the optimal treatment strategy for SCCC. Methods: This was a multicenter retrospective study. Medical records of patients with pathologically proven SCCC treated between 2003 and 2016 were retrospectively analyzed. Overall survival (OS) was plotted using the Kaplan-Meier method. Log-rank tests and Cox regression analysis were used to assess the differences in survival according to stage, treatment strategy, and chemotherapy regimen. Results: Data of 78 patients were collected, and after excluding patients without immunohistopathological staining, 65 patients were evaluated. The median age of the included patients was 47 (range: 24–83) years. The numbers of patients with International Federation of Gynecology and Obstetrics (FIGO) 2018 stages I-IIA, IIB-IVA, IVB were 23 (35%), 34 (52%), and 8 (12%), respectively. Of 53 patients who had undergone chemotherapy, 35 and 18 received SCCC and non-SCCC regimens as their first-line chemotherapy regimen, respectively. The 5-year OS for all patients was 49%, while for patients with FIGO stages I-IIA, IIB-IVA, IVB, it was 60, 50, and 0%, respectively. The 5-year OS rates for patients who underwent treatment with SCCC versus non-SCCC regimens were 59 and 13% (p < 0.01), respectively. This trend was pronounced in locally advanced stages. Multivariate analysis showed that FIGO IVB at initial diagnosis was a significant prognostic factor in all patients. Among the 53 patients who received chemotherapy, the SCCC regimen was associated with significantly better 5-year OS in both the uni- and multivariate analyses. Conclusion: Our results suggest that the application of an SCCC regimen such as EP or IP as first-line chemotherapy for patients with locally advanced SCCC may play a key role in OS. These findings need to be validated in future nationwide, prospective clinical studies.

    DOI: 10.1186/s12885-021-08772-x

    Web of Science

    Scopus

    PubMed

  19. Can we safely lower the RT dose with the use of high dose PF for advanced cervical cancer? 査読有り

    Kawamura, M; Nakahara, R; Ishihara, S; Oie, Y; Takase, Y; Okumura, M; Ito, J; Ono, T; Itoh, Y; Naganawa, S

    RADIOTHERAPY AND ONCOLOGY   161 巻   頁: S1064 - S1065   2021年8月

     詳細を見る

  20. Phase I/II study of intraoperative radiotherapy for early breast cancer in Japan.

    SAWAKI MASATAKA, SATO SHIGENORI, NODA SUMIYO , IDOTA AI , UCHIDA HIROKI ,TSUNODA NOBUYUKI, KIKUMORI TOYONE , AOYAMA YUICHI, ISHIHARA SHUNICHI , ITOH YOSHIYUKI, IMAI TSUNEO

    Breast Cancer     頁: .   2011年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  21. Relationship Between Hematotoxicity and Serum Albumin Level in the Treatment of Head and Neck Cancers with Concurrent Chemoradiotherapy Using Cisplatin.

    ISHIZUKA MASAKO, FUJIMOTO YASUSHI, ITOH YOSHIYUKI, KITAGAWA KOICHI, SANO MOTOKI, MIYAGAWA YASUHIRO,ANDO ATSUSHI, HIRAMATSU MARIKO, HIRASAWA NAOKI, ISHIHARA SHUNICHI, NAKASHIMA TSUTOMU, YAMADA KIYOFUMI

    Jpn J Clin Oncol   41 巻 ( 8 ) 頁: 973-979   2011年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  22. MR imaging of the Cochlear Modiolus after Intratympanic Administration of Gd-DTPA

    KAWAI HISASHI, NAGANAWA SHINJI, ISHIHARA SHUNICHI, SONE MICHIHIKO, NAKASHIMA TSUTOMU

    Magn Reson Med Sci   9 巻 ( 1 ) 頁: 23-29   2010年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  23. Simultaneous three-dimensional visualization of the intra-parotid facial nerve and parotid duct using a three-dimensional reversed FISP sequence with diffusion weighting.

    NAGANAWA SHINJI, ISHIHARA SHUNICHI, SATAKE HIROKO, KAWAI HISASHI, SONE MICHIHIKO, NAKASHIMA TSUTOMU

    Magn Reson Med Sci   9 巻   頁: 153-158   2010年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  24. Estimation of Gadolinium-induced T(1)-shortening with Measurement of Simple Signal Intensity Ratio between the Cochlea and Brain Parenchyma on 3D-FLAIR: Correlation with T(1) Measurement by TI Scout Sequence.

    NAGANAWA SHINJI, ISHIHARA SHUNICHI, IWANO SHINGO, KAWAI HISASHI, SONE MICHIHIKO, NAKASHIMA TSUTOMU

    Magn Reson Med Sci   9 巻 ( 1 ) 頁: 17-22   2010年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  25. Radiotherapy with or without chemotherapy for patients with T1-T2 glottic carcinoma: retrospective analysis.

    HIRASAWA NAOKI, ITOH YOSHIYUKI ISHIHARA SHUNICHI, KUBOTA SEIJI, ITOH JUNJI, FUJIMOTO YASUSHI, NAKASHIMA TSUTOMU, NAGANAWA SHINJI

    Head Neck Oncol   2 巻 ( 20 )   2010年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  26. 早期声門癌に対する治療方針に関するアンケート調査 耳鼻科医を対象とした調査結果

    平澤直樹、伊藤善之、石原俊一、長縄慎二、鈴木一徳、野本由人、村尾豪之、堀川よしみ、小山一之、笹岡政宏、浅野晶子、小幡康範

    臨床放射線   55 巻   頁: 541-546   2010年5月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

  27. Three-dimensional (3D) visualization of endolymphatic hydrops after intratympanic injection of Gd-DTPA: optimization of a 3D-real inversion-recovery turbo spin-echo (TSE) sequence and application of a 32-channel head coil at 3T.

    NAGANAWA SHINJI, ISHIHARA SHUNICHI, IWANO SHINGO, SONE MICHIHIKO, NAKASHIMA TSUTOMU

    JOURNAL OF MAGNETIC RESONANCE IMAGING   31 巻   頁: 210-214   2010年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  28. Detection of presumed hemorrhage in the ampullar endolymph of the semicircular canal: a case report.

    NAGANAWA SHINJI, ISHIHARA SHUNICHI, IWANO SHINGO, SONE MICHIHIKO, NAKASHIMA TSUTOMU

    Magn Reson Med Sci   8 巻   頁: 187-191   2010年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  29. A Phase I Study of Intraoperative Radiotherapy for Early Breast Cancer in Japan

    Masataka Sawaki , Shigenori Sato,Toyone Kikumori ,Shunichi Ishihara ,Yuichi Aoyama, Yoshiyuki Itoh ,Akimasa Nakao , Tsuneo Imai

    World J Surg   33 巻   頁: 2587-2592   2009年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  30. Primary central nervous system lymphoma in Japan: changes in clinical features, treatment, and prognosis during 1985-2004

    Shibamoto Y, Ogino H, Suzuki G, Takemoto M, Araki N, Isobe K, Tsuchida E, Nakamura K, Kenjo M, Suzuki K, Hosono M, Tokumaru S, Ishihara S, Kato E, Ii N, Hayabuchi N

    Neuro Oncol   10 巻 ( 4 ) 頁: 560-568   2008年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  31. *Incidence of brain atrophy and decline in Mini-Mental State Examination Score after whole-brain radiotherapy in patients with brain metastases: A prospective study.

    Shibamoto Y, Baba F, Oda K, Hayashi S, Kokubo M, Ishihara S, Itoh Y, Ogino H, Koizumi M

    Int. J. Radiation Oncology Biol. Phys.   72 巻 ( 4 ) 頁: 1168-1173   2008年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  32. *Intraarterial cisplatin/nedaplatin and intravenous 5-fluorouracil with concurrent radiation therapy for patients with high-risk uterine cervical cancer. 査読有り

    Kawase S, Okuda T, Ikeda M, Ishihara S, Itoh Y, Yanagawa S, Ishigaki T

    Gynecol Oncol.   102 巻 ( 3 ) 頁: 493-499   2006年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVE: The purpose of this study was to determine the effectiveness of the combination of intraarterial and intravenous concurrent chemoradiation therapy (CIAIV-CCRT) for the treatment of high-risk uterine cervical cancer. METHODS: Between January 2000 and November 2004, we reviewed 45 cervical cancer patients treated by CIAIV-CCRT. The numbers of patients with stage IB2, IIA, IIB, IIIA, IIIB, and IVA were 3, 6, 14, 1, 17, and 4, respectively. Patients with stage III and IVA or patients with tumors >3 cm in diameter were enrolled in this study. Two sessions of CCRT were administered every 3 weeks using a combination of 70 mg/m2 x h(-1) cisplatin or 50 mg/m2 x h(-1) nedaplatin via the bilateral uterine artery and 2800 mg/m2 x 96 h(-1) 5-fluorouracil intravenously. Patients concurrently received external beam radiation therapy and brachytherapy. A nonrandomized control group of 47 patients who underwent radiation therapy alone between 1993 and 2000 was used for comparison. RESULTS: Of the 45 patients, 28 (62%) exhibited complete response and 16 (36%) exhibited partial response. One IIIB patient (2%) did not show any response. The 5-year overall survival (OAS) rates in the CCRT group and control group were 80.6% and 54.9%, respectively. With regard to late toxicities, no statistically significant differences were observed between the two groups. In uni- and multivariate analyses, positive pelvic lymph node showed a statistically significant influence on the OAS in the CIAIV-CCRT group (P = 0.049). CONCLUSION: These preliminary results suggest that CIAIV-CCRT can improve the prognosis of patients with high-risk cervical cancer.

  33. 限局性前立腺癌に対する3次元原体照射法における至適照射体位に関する研究

    加藤貴弘、小幡康範、柳川繁雄、石原俊一、青山裕一、島田秀樹、村山洋

    日本放射線腰療学会誌   18 巻 ( 4 ) 頁: 235-242   2006年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

  34. 化学放射線治療後、長期にわたりT2高信号を呈した子宮頭痛の1例

    中村達也、伊藤善之、石原俊一、河井通泰、前多松喜

    Japanese Journal of Diagnostic Imaging   26 巻   頁: 1416-1419   2006年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

  35. 非小細胞肺癌の放射線治療成績

    岡田徹, 石原俊一, 伊藤善之, 石垣武男, 柳川繁雄, 堀川よしみ, 奥田隆仁

    日本医学放射線学会雑誌   214 巻   2006年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

  36. Results of Primary Central Nervous System Lymphoma Treated by Radiation and Chemotherapy: Retrospective Analysis of Twelve Institutions in the Tokai District of Japan, 1995-1999. 査読有り

    Kawamura K, Ishiguchi T, Shibamoto Y, Ogino H, Ishihara S, Yamada T, Katada K, Suzuki K, Suzuki H, Mimura M

    Radiation Medicine   24 巻   頁: 9-16   2006年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PURPOSE: We analyzed the therapeutic results and prognostic factors of 46 primary central nervous system lymphoma (PCNSL) patients who were treated at twelve institutions in the Tokai district of Japan between 1995 and 1999. We compared the results with those of a Japanese nationwide survey performed in the past. MATERIALS AND METHODS: We sent each institution a questionnaire about the state of patients' disease, pathological type, method and doses of radiotherapy, regimen and intensity of chemotherapy, and patients' prognoses. The range of patients' ages was 33 to 93 years (median, 61 years). Thirty-one were men and 15 were women. The most prevalent histology was diffuse large B cell type (33 patients). We used the Kaplan-Meier method to calculate the survival rate and Cox's proportional hazards model to analyze the prognostic factors. RESULTS: The five-year cumulative survival rate was 25%, and the median survival time was 22.7 months. The five-year disease-free survival rate was 23%. In monovariate analysis, patients who were both younger than 60 years old and had a WHO performance status (PS) score equal to or less than 2 showed a better survival rate. Furthermore, the patients receiving systemic chemotherapy showed a significantly better local control rate. In addition, patients who received systemic chemotherapy achieved a higher complete remission rate than those not receiving it. However, no factors that significantly influenced survival rate were identified in multivariate analysis. CONCLUSION: We demonstrated that the therapeutic outcome of PCNSL patients has recently improved. In particular, patients with good PS showed better local control than those with poor PS. However, we could not identify any significant prognostic factors in PCNSL patients.

  37. *CNS germinoma with elevated serum human chorionic gonadtropin level: clinical characteristics and treatment outcome. 査読有り

    Ogino H, Shibamoto Y, Takanaka T, Suzuki K, Ishihara S, Yamada T, Sugie C, Nomoto Y, Mimura M.

    International Journal of Radiation Oncology Biology Physics   62 巻   頁: 803-808   2005年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PURPOSE: The prognostic significance of human chorionic gonadotropin (HCG) level in central nervous system germinoma remains controversial. The purpose of this study was to compare clinical characteristics and prognosis of germinoma patients with normal and high HCG titers in the serum. METHODS AND MATERIALS: We undertook a multi-institutional retrospective analysis of 103 patients with central nervous system germinoma whose serum HCG and/or beta-HCG level had been measured before treatment between 1984 and 2002. All patients had been treated with radiation therapy either alone (n = 66) or in combination with chemotherapy (n = 37) with a median dose of 47.8 Gy. RESULTS: HCG and/or beta-HCG level in the serum was high in 39% of all patients. The proportion of HCG-producing tumors was higher in the lesions at the basal ganglia than in the lesions at the other sites. No correlation was found between tumor size and HCG level, but there seemed to be a weak correlation between size and beta-HCG. The 5- and 10-year survival rates were 96% and 94%, respectively, in both patient groups with normal and high HCG (p = 0.99). The 5- and 10-year relapse-free survival rates were 87% and 82%, respectively, in patients with normal HCG level and were both 87% in patients with high HCG (p = 0.74). Also, no other patient-, tumor-, or treatment-related factors seemed to influence the prognosis of the patients. CONCLUSION: Serum HCG level does not seem to influence patient prognosis when treated with sufficient doses of radiation. Relationship between tumor size and site and HCG level should be investigated further.

  38. *Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. 査読有り

    Shibamoto Y, Ogino H, Hasegawa M, Suzuki K, Nishio M, Fujii T, Kato E, Ishihara S, Sougawa M, Kenjo M, Kawamura T, Hayabuchi N.

    International Journal of Radiation Oncology Biology Physics   62 巻   頁: 809-813   2005年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PURPOSE: To investigate whether the prognosis of primary central nervous system lymphoma (PCNSL) patients treated by radiation alone remains still poor, we investigated the results of radiation monotherapy in the 1990s. METHODS AND MATERIALS: We collected data on 132 patients with histologically proven PCNSL treated by radiation alone in the 1990s. Follow-up data were updated as far as possible. Eleven patients who did not complete planned radiotherapy were included. The data were analyzed in relation to patient and tumor characteristics. The median patient age was 63 years, and the World Health Organization performance status (PS) was 3 or 4 in 40% of the patients. Multiple tumors were seen in 34%. Whole-brain irradiation with or without focal boost was used in 92%. The median radiation dose to the tumor site was 50 Gy (range, 8-74 Gy). RESULTS: For all 132 patients, the median survival time was 18 months and the 5-year survival rate was 18.0%. For 62 patients with PS 0-3 and aged 16-65 years (i.e., those eligible for the European Organization for Research and Treatment of Cancer 20962 study), the median survival was 26 months and 5-year survival was 24%. The 5-year survival was 25% for patients 63 years old or younger, and 9.8% for those older than 63 years (p = 0.0005). The 5-year survival was 22% for patients with PS 0-2 and 13% for those with PS 3 or 4 (p = 0.0040). Multivariate analysis confirmed the negative influence of higher age on patient prognosis. CONCLUSIONS: The results of radiation monotherapy for PCNSL appear to have improved as compared with those reported previously. The results of new treatment should be evaluated in light of this finding. Since most prospective studies on the combined treatment exclude poor PS and high-age patients, the 5-year survival rate of 30% may not be regarded as a marked improvement over radiation alone.

  39. Serial evaluation of diffusion tensor brain fiber tracking in a patient with severe diffuse axonal injury.

    Naganawa S, Sato C, Ishihara S, Kumada H, Ishigaki T, Miura S, Watanabe M, Maruyama K, Takizawa O

    AJNR Am J Neuroradiol   25 巻 ( 9 ) 頁: 1553-1556   2004年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  40. 婦人科悪性腫瘍に対する化学放射線療法 5-FUとNedaplatinの投与順序と血液毒性

    伊藤善之, 石原俊一, 熊田倫, 高井勝文, 岩田正光, 中村達也, 川瀬世津子, 鈴木耕次郎, 森芳峰, 平澤直樹, 佐藤千峰, 福嶋洋道, 奥田隆仁, 太田豊裕, 柳川繁雄, 石垣武男

    癌と化学療法   31 巻 ( 5 ) 頁: 797-799   2004年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

  41. *CRT diagnosis of pulmonary disease: influence of monitor brightness and room illuminance on observer performance. 査読有り

    Ishihara S, Shimamoto K, Ikeda M, Kato K, Mori Y, Ishiguchi T, Ishigaki T.

    Computerized Medical Imaging and Graphics   26 巻   頁: 181-185   2002年

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Using a 21-in. cathode ray tube (CRT) monitor (2048 x 2560 x 8bits), six radiologists interpreted 12 images with interstitial lung disease under six conditions of CRT luminance (50 and 400 cd/m(2)) and room illuminance (20, 120 and 480lx), and 10 radiologists interpreted 25 images with pulmonary nodules under nine conditions of CRT luminance (50, 200 and 500 cd/m(2)) and room illuminance (20, 120 and 480lx). Observer's performance for interstitial disease was relatively better at 120lx. Four hundred and eighty lux illuminance with 50 cd/m(2) CRT luminance, which degraded the detectability of pulmonary nodule significantly (p<0.05), should be avoided for clinical use.

  42. 高輝度・高精細のCRTモニターの観察条件に関する研究(第1報)

    石垣武男、島本佳寿広、池田充、石原俊一、加藤克彦

    コニカⅩ-レイ写真研究51巻3号   98 巻 ( 100 )   2000年

     詳細を見る

    記述言語:日本語  

  43. クライアント・サーバー型ネットワークを用いた放射線科業務支援システム

    廣田英輝、石原俊一、岩野信吾、市川詠子、中根基、新家靖、平野仁、牧野直樹

    トヨタ医報8巻   23 巻 ( 31 )   1998年

     詳細を見る

    記述言語:日本語  

▼全件表示

書籍等出版物 1

  1. やさしくわかる放射線治療学

    公益社団法人 日本放射線腫瘍学会( 担当: 編集 ,  範囲: 第5章 放射線治療のための生物学)

    学研メディカル秀潤社  2018年10月 

     詳細を見る

    総ページ数:209   記述言語:日本語 著書種別:教科書・概説・概論

講演・口頭発表等 54

  1. 前立腺癌に対するスペーサーゲル留置下での定位照射後に直腸穿孔を生じた一例

    柳 裕介 山田 剛大 大家 祐実 香西 由加 奥村 真之 青木 すみれ 安井 遼太郎 川村 麻里子 石原 俊一 長縄 慎二 石田昇平 澤田つな騎

    日本医学放射線学会 第174回中部地方会  2024年2月18日  日本医学放射線学会 中部地方会

     詳細を見る

    開催年月日: 2024年2月

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:名古屋市   国名:日本国  

  2. COVID-19流行下で使用した放射線治療教育の教材共有とその活用

    前林俊也、加藤徳雄、畑山佳臣、石原俊一、石原武明、高岡大樹、野本由人

    日本放射線腫瘍学会 第36回学術大会  2023年12月1日  日本放射線腫瘍学会

     詳細を見る

    開催年月日: 2023年11月 - 2023年12月

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(指名)  

    開催地:横浜市   国名:日本国  

  3. 心臓原発横紋筋肉腫への放射線治療後、長期フォローアップ中に心不全を発症した1例

    青木すみれ、川村麻里子、石原俊一、大家祐実、香西由加、山田剛大、奥村真之、安井遼太郎、柳裕介、二村健太、野口正宗、村木昂大、長縄慎二、西尾信博

    日本放射線腫瘍学会 第36回学術大会  2023年12月1日  日本放射線腫瘍学会

     詳細を見る

    開催年月日: 2023年11月 - 2023年12月

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:横浜市   国名:日本国  

  4. 少数常勤医問題小委員会の活動報告

    石原俊一、渥美和重、今井美智子、坂本隆吏、西多俊幸、野中哲生、福田晴行、伏木雅人

    日本放射線腫瘍学会 第36回学術大会  2023年12月1日  日本放射線腫瘍学会

     詳細を見る

    開催年月日: 2023年11月 - 2023年12月

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(指名)  

    開催地:横浜市   国名:日本国  

  5. 当院における食道癌に対する根治的放射線治療の後方視的解析

    安井遼太郎、石原俊一、 川村麻里子、大家祐実、 香西由加、山田剛大、奥村真之、 青木すみれ、柳 裕介、 二村健太、野口正宗、村木昂大、 長縄慎二

    日本医学放射線学会 第173回中部地方会  2023年7月9日  日本医学放射線学会 中部地方会

     詳細を見る

    開催年月日: 2023年7月

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:石川県河北郡内灘町   国名:日本国  

  6. 医療の質:治療

    石原俊一

    第82回 日本医学放射線学会総会  2023年4月16日  日本医学放射線学会

     詳細を見る

    開催年月日: 2023年4月

    記述言語:日本語   会議種別:公開講演,セミナー,チュートリアル,講習,講義等  

    開催地:横浜市   国名:日本国  

  7. 同時化学放射線療法において線量低減を行った子宮頸がんの後ろ向き研究

    長井尚哉、川村麻里子、石原俊一、大家祐実、香西由加、髙瀬裕樹、奥村真之、進藤由香里、安井遼太郎、柳裕介、長縄慎二

    日本医学放射線学会 第172回中部地方会  2023年2月12日  日本医学放射線学会 中部地方会

     詳細を見る

    開催年月日: 2023年2月

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:桑名市   国名:日本国  

  8. 食道癌術後局所領域再発に対する救済照射

    奥村真之、石原俊一、宮田一志、神田光郎、古川和宏、前田修、川村麻里子、大家祐実、香西由加、髙瀬裕樹、青木すみれ、柳裕介、長縄慎二

    日本放射線腫瘍学会 第35回学術大会  2022年11月10日  日本放射線腫瘍学会

     詳細を見る

    開催年月日: 2022年11月

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:広島市   国名:日本国  

  9. 乳房全切除術後放射線治療におけるボーラス省略妥当性の検討

    進藤由里香、川村麻里子、奥村真之、石原俊一、大家祐実、香西由加、髙瀬裕樹、小野玉美、青木すみれ、長縄慎二

    日本放射線腫瘍学会 第35回学術大会  2022年11月12日  日本放射線腫瘍学会

     詳細を見る

    開催年月日: 2022年11月

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:広島市   国名:日本国  

  10. I-125シード線源バッチ測定に向けた補正係数の導出

    村松海飛、加茂前健、小口宏、末沢正太郎、奥平訓康、矢谷朋子、森政樹、阿部真治、石原俊一、長縄慎二

    第124回日本医学物理学会学術学会  2022年9月 

     詳細を見る

    開催年月日: 2022年9月

    記述言語:日本語  

    開催地:長崎   国名:日本国  

  11. 食道癌術後局所領域再発に対する救済照射

    奥村真之、石原俊一、川村麻里子、大家祐実、香西由加、髙瀬裕樹、青木すみれ、柳裕介、長縄慎二、宮田一志、神田光郎、古川和宏、前田修

    日本医学放射線学会 第171回中部地方会  2022年7月 

     詳細を見る

    開催年月日: 2022年7月

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:浜松市   国名:日本国  

  12. 胸部放射線治療後の長期フォローアップ中に心不全を発症した1例

    青木すみれ、川村麻里子、石原俊一、大家祐実、香西由加、髙瀬裕樹、奥村真之、小野玉美、柳裕介、長縄慎二

    日本医学放射線学会 第171回中部地方会  2022年7月 

     詳細を見る

    開催年月日: 2022年7月

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:浜松市   国名:日本国  

  13. PMRT without bolus is feasible 国際会議

    Yurika Shindo, Mariko kawamura, Masayuki Okumura, Shunichi Ishihara, Yumi Oie, Yuki Takase, Naoya Nagai, Sumire Aoki, Ryotaro Yasui, Shinji Naganawa

    Global Breast Cancer Conference 2022  2022年4月 

     詳細を見る

    開催年月日: 2022年4月

    記述言語:英語  

    開催地:Seoul   国名:大韓民国  

  14. 転移性脳腫瘍に対するVero 4DRTを用いた厳格な適応基準に基づくsingle fraction SRSの治療成績

    山田剛大、伊藤淳二、石原俊一、加茂前健、長縄慎二、大宝和博

    第35回 高精度放射線外部照射部会学術大会 

     詳細を見る

    開催年月日: 2022年3月

    記述言語:日本語  

    国名:日本国  

  15. 乳房全切除後照射にボーラスは必要か

    進藤由里香、奥村真之、川村麻里子、石原俊一、大家祐実、髙瀬裕樹、長井尚哉、青木すみれ、安井遼太郎、長縄慎二

    日本医学放射線学会 第170回中部地方会  2022年2月 

     詳細を見る

    開催年月日: 2022年2月

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:web  

  16. 転移性脳腫瘍に対するVero 4DRTを用いた定位放射線照射後の要治療介入放射線障害例の検討

    山田剛大、伊藤淳二、石原俊一、加茂前健、長縄慎二、大宝和博

    第13回 放射線外科学会 

     詳細を見る

    開催年月日: 2022年2月

    記述言語:日本語  

    国名:日本国  

  17. 当院における食道癌の放射線治療成績

    石原俊一、山田剛大、山本英子、長縄慎二

    日本放射線腫瘍学会第34回学術大会 

     詳細を見る

    開催年月日: 2021年11月

    記述言語:日本語  

    国名:日本国  

  18. 間質性肺疾患を有するがん患者における緩和照射後の放射線肺臓炎

    奥村真之、北條秀博、中村匡希、檜山貴志、中村直樹、全田貞幹、茂木厚、平田秀成、平野靖弘、影山俊一郎、藤澤建志、久野博文、秋元哲夫、石原俊一、長縄慎二

    日本放射線腫瘍学会 第34回学術大会 

     詳細を見る

    開催年月日: 2021年11月

    記述言語:日本語  

    国名:日本国  

  19. Can we safety lower the RT dose with the use of high dose PF for advanced cervical cancer? 国際会議

    Mariko Kawamura, Rie Nakahara, Shunichi Ishihara, Yumi Oie, Yuki Takase, Masayuki Okumura, Junji Ito, Tamami Ono, Yoshiyuki Itoh, Shinji Naganawa

    The European Society for Radiotherapy and Oncology (ESTRO) 2021 

     詳細を見る

    開催年月日: 2021年8月

    記述言語:英語  

  20. 当院における食道癌の放射線治療成績

    石原俊一、山田剛大、山本英子、長縄慎二

    日本医学放射線学会第169回中部地方会 

     詳細を見る

    開催年月日: 2021年7月

    記述言語:日本語  

    国名:日本国  

  21. 肝細胞癌に対するサイバーナイフを用いた体幹部定位放射線治療の遡及的検討

    奥村真之、奥田隆仁、髙瀬裕樹、鈴木淳司、川村麻里子、長縄慎二、石原俊一

    日本医学放射線学会第169回中部地方会 

     詳細を見る

    開催年月日: 2021年7月

    記述言語:日本語  

    国名:日本国  

  22. 子宮頸部小細胞癌の治療法とその予後に関する実態調査

    川村麻里子、小出雄太郎、村井太郎、石原俊一、髙瀬裕樹、村尾豪之、岡崎大、山口尊弘、内山薫、伊藤善之、古平毅、芝本雄太、水野美香、吉川史隆、長縄慎二

    第62回日本婦人科腫瘍学会学術講演会 

     詳細を見る

    開催年月日: 2021年1月 - 2021年2月

    記述言語:日本語  

    国名:日本国  

  23. 乳房温存手術・術中放射線照射の安全性と有効性に関する第1/2 相試験

    伊藤善之、石原俊一、平澤直樹、久保田誠司、牧 紗代、中原理絵、長縄慎二

    日本放射線腫瘍学会 第23回学術大会 

     詳細を見る

    開催年月日: 2010年11月

    記述言語:日本語  

    国名:日本国  

  24. 非小細胞肺癌に対する放射線治療成績

    石原俊一、中原理絵、牧紗代、久保田誠司、平澤直樹、伊藤善之、長縄慎二

    日本放射線腫瘍学会 第23回学術大会 

     詳細を見る

    開催年月日: 2010年11月

    記述言語:日本語  

    国名:日本国  

  25. 乳癌に対する術中照射

    石原俊一

    第46回日本医学放射線学会秋季臨床大会 

     詳細を見る

    開催年月日: 2010年9月

    記述言語:日本語  

    国名:日本国  

  26. 非小細胞肺癌に対する放射線治療成績

    石原俊一、中原理絵、牧 紗代、久保田誠司、平澤直樹、伊藤善之、長縄慎二

    日本医学放射線学会第148回中部地方会 

     詳細を見る

    開催年月日: 2010年6月

    記述言語:日本語  

    国名:日本国  

  27. 子宮頸癌の根治的放射線治療成績

    久保田誠司、中原理絵、牧 紗代、平澤直樹、石原俊一、伊藤善之、長縄慎二、奥田隆仁、堀川よしみ

    日本医学放射線学会第148回中部地方会 

     詳細を見る

    開催年月日: 2010年6月

    記述言語:日本語  

    国名:日本国  

  28. 高齢者子宮頸癌の根治的放射線治療成績

    久保田誠司、伊藤善之、伊藤淳二、牧 紗代、平澤直樹、石原俊一、長縄慎二

    日本医学放射線学会第147回中部地方会 

     詳細を見る

    開催年月日: 2010年2月

    記述言語:日本語  

    国名:日本国  

  29. 転移性脳腫瘍に対する放射線治療の成績

    奥田隆二、櫻井悠介、浅野晶子、熊田倫、石原俊一、久保田誠司、伊藤淳二、伊藤善之、長縄慎二

    日本医学放射線学会第147回中部地方会 

     詳細を見る

    開催年月日: 2010年2月

    記述言語:日本語  

    国名:日本国  

  30. 金属冠による放射線治療時の口腔粘膜への影響について その1

    伊藤淳二、伊藤善之、平澤直樹、久保田誠司、石原俊一、牧 紗代、長縄慎二、五十嵐幸哲、下郷智弘、小幡 康、青山裕一、奥平訓康、野口由美子、都築 真、平松真理子、安藤篤、藤本 保、山本憲幸

    日本医学放射線学会第147回中部地方会 

     詳細を見る

    開催年月日: 2010年2月

    記述言語:日本語  

  31. 頭頸部癌に対するシスプラチン同時併用放射線治療の検討

    石塚雅子、藤本保志、伊藤善之、石原俊一、佐野元基、山田清文、安藤篤、平松真理子、加藤健、佐野塁、鈴木秀典、中島務

    第27回東海頭頸部腫瘍研究会 

     詳細を見る

    開催年月日: 2010年1月

    記述言語:日本語  

    国名:日本国  

  32. 転移性脳腫瘍に対する定位放射線治療の成績

    奥田隆仁、櫻井悠介、浅野晶子、熊田倫、島田秀樹、石原俊一、久保田誠司、伊藤淳二、伊藤善之、長縄慎二

    日本放射線腫瘍学会 第22回学術大会 日本医学物理学会 第98回学術大会 

     詳細を見る

    開催年月日: 2009年9月

    記述言語:日本語  

    国名:日本国  

  33. 悪性神経膠腫の放射線治療成績

    石原俊一、伊藤淳二、久保田誠司、平澤直樹、伊藤善之、長縄慎二

    日本放射線腫瘍学会 第22回学術大会 日本医学物理学会 第98回学術大会 

     詳細を見る

    開催年月日: 2009年9月

    記述言語:日本語  

    国名:日本国  

  34. 早期声門癌に対する多施設の遡及的調査

    平澤直樹、伊藤善之、石原俊一、長縄慎二、小幡康範、鈴木一徳、小山一之、村尾豪之、野本由人、堀川よしみ

    日本放射線腫瘍学会 第22回学術大会 日本医学物理学会 第98回学術大会 

     詳細を見る

    開催年月日: 2009年9月

    記述言語:日本語  

    国名:日本国  

  35. 子宮頸癌化学放射線療法における卵巣機能温存の試み

    奥田隆仁、伊藤信嗣、松尾啓治、下川剛、小口秀紀、石原俊一、平澤直樹、伊藤善之、長縄慎二、青山裕一

    日本医学放射線学会第146回中部地方会 

     詳細を見る

    開催年月日: 2009年6月

    記述言語:日本語   会議種別:口頭発表(一般)  

    国名:日本国  

  36. 悪性神経膠腫の放射線治療成績

    石原俊一、伊藤淳二、久保田誠司、平澤直樹、伊藤善之、長縄慎二、若林俊彦、藤井正純、池田充

    日本医学放射線学会第146回中部地方会 

     詳細を見る

    開催年月日: 2009年6月

    記述言語:日本語   会議種別:口頭発表(一般)  

    国名:日本国  

  37. 異なった予後を示した子宮頚部小細胞癌の2例

    奥田隆仁、松尾啓司、浅野晶子、熊田 倫、河合通泰、石原俊一、伊藤善之、長縄慎二

    日本医学放射線学会第145回中部地方会 

     詳細を見る

    開催年月日: 2009年2月

    記述言語:日本語  

    国名:日本国  

  38. 放射線治療を施行した転移性脳腫瘍の予後因子

    日本放射線腫瘍学会第21回学術大会 

     詳細を見る

    開催年月日: 2008年10月

    記述言語:日本語  

    国名:日本国  

  39. 放射線治療を施行した転移性脳腫瘍の予後因子

    石原俊一、伊藤淳二、久保田誠司、平澤直樹、伊藤善之、長縄慎二、池田充

    日本医学放射線学会第144回中部地方会 

     詳細を見る

    開催年月日: 2008年7月

    記述言語:日本語  

    国名:日本国  

  40. 頭頸部癌に対するS-1併用化学放射線療法の臨床第1相試験

    伊藤善之、平澤直樹、岡田徹、石原俊一、久保田誠司、伊藤淳二、長縄慎二

    第67回日本医学放射線学会総会 

     詳細を見る

    開催年月日: 2008年4月

    記述言語:日本語  

  41. 子宮頸癌治療中に意識障害となり、MRIにて脳幹背側から視床に異常信号を認めた1例

    戸谷麗子、岡田徹、川井恒、石原俊一、伊藤善之、長縄慎二

    日本医学放射線学会 第143回中部地方会 

     詳細を見る

    開催年月日: 2008年2月

    記述言語:日本語  

    国名:日本国  

  42. 子宮頸癌化学放射線療法中に高アンモニア血症を呈した1例

    岡田徹、戸谷麗子、伊藤淳二、久保田誠司、平澤直樹、川井恒、石原俊一、伊藤善之、長縄慎二、河田健司、安藤雄一

    日本医学放射線学会 第143回中部地方会 

     詳細を見る

    開催年月日: 2008年2月

    記述言語:日本語  

    国名:日本国  

  43. 乳房温存術後の術中照射による短期照射法第1報 臨床実験の概要と初期報告

    伊藤善之、石原俊一、岡田徹、平澤直樹、久保田誠司、伊藤淳二、長縄慎二、今井常夫、澤木正孝

    日本医学放射線学会 第143回中部地方会 

     詳細を見る

    開催年月日: 2008年2月

    記述言語:日本語  

    国名:日本国  

  44. 頭頸部癌に対するTS-1併用化学放射線療法の臨床第Ⅰ相試験

    伊藤善之、平澤直樹、岡田徹、石原俊一、久保田誠司、伊藤淳二、長縄慎二、加藤賢史、藤本保志、中島務

    日本医学放射線学会 第143回中部地方会 

     詳細を見る

    開催年月日: 2008年2月

    記述言語:日本語  

    国名:日本国  

  45. 早期声門癌に対する根治的放射線治療の遡及的検討

    平澤直樹、石原俊一、岡田徹、久保田誠司、伊藤淳二、伊藤善之、長縄慎二、堀川よしみ

    日本医学放射線学会 第143回中部地方会 

     詳細を見る

    開催年月日: 2008年2月

    記述言語:日本語  

    国名:日本国  

  46. 前立腺癌に対する緩和的放射線治療

    第7回NPCフォーラム 

     詳細を見る

    開催年月日: 2008年2月

    記述言語:日本語  

    国名:日本国  

  47. 放射線治療を施行した骨転移患者の予後

    石原俊一、久保田誠司、平澤直樹、岡田 徹、伊藤善之、長縄慎二、奥田隆仁

    日本放射線腫瘍学会第20回学術大会 

     詳細を見る

    開催年月日: 2007年12月

    記述言語:日本語  

    国名:日本国  

  48. 脈絡膜悪性黒色腫に対する炭素イオン線治療

    平澤直樹、伊藤善之、石原俊一、岡田徹、長縄慎二、辻比呂志、加藤弘之、野宮琢麿、鎌田正、溝江純悦、辻井博彦

    日本医学放射線学会第141回中部地方会 

     詳細を見る

    開催年月日: 2007年2月

    記述言語:日本語  

    国名:日本国  

  49. 食道癌放射線治療による冠動脈と刺激伝導系の影響

    岡田徹、伊藤淳二、久保田誠司、平澤直樹、石原俊一、伊藤善之

    東海がんプロフェッショナル養成プラン 食道癌 院外公開カンファレンス 

     詳細を見る

    開催年月日: 2007年2月

    記述言語:日本語  

    国名:日本国  

  50. Radiotherapy for Anal Canal Cancer in Japan : A Retrospective Multi-Institutional Study. 国際会議

    ASTRO'S 48th Annual Meeting 

     詳細を見る

    開催年月日: 2006年11月

    記述言語:英語  

  51. 非小細胞肺癌の治療成績

    岡田徹、石原俊一、伊藤善之、石垣武男、柳川繁雄、堀川よしみ、奥田隆仁

    第65回日本医学放射線学会学術集会 

     詳細を見る

    開催年月日: 2006年4月

    記述言語:日本語  

    国名:日本国  

  52. 名古屋大学医学部附属病院における非小細胞癌の治療成績

    岡田徹、石原俊一、奥田隆仁、堀川よしみ、伊藤善之、石垣武男

    日本医学放射線学会第139回中部地方会 

     詳細を見る

    開催年月日: 2006年2月

    記述言語:日本語  

    国名:日本国  

  53. 声門癌の放射線治療成績

    石原俊一、伊藤善之、石垣武男、柳川繁雄、中村達也、奥田隆仁

    日本放射線腫瘍学会 第18回学術大会 

     詳細を見る

    開催年月日: 2005年11月

    記述言語:日本語   会議種別:ポスター発表  

    国名:日本国  

  54. 脳室と無関係に発生したコロイド囊胞の1 例

    中村達也、 石原俊一、熊田 倫

    第62回名古屋レントゲンカンファランス 

     詳細を見る

    開催年月日: 2004年9月

    記述言語:日本語  

▼全件表示

 

担当経験のある科目 (本学) 7

  1. 放射線腫瘍学特論

    2023

     詳細を見る

    前立腺癌、骨転移の放射線治療

  2. 放射線科系統講義

    2023

     詳細を見る

    有害事象、緩和照射

  3. 放射線腫瘍学特論

    2022

     詳細を見る

    前立腺癌、骨転移の放射線治療

  4. 放射線治療技術学Ⅰ

    2022

  5. 放射線科系統講義

    2022

  6. 放射線腫瘍学特論

    2021

  7. 放射線治療技術学Ⅰ

    2021

     詳細を見る

    放射線治療の臨床について、症例提示を中心に講義した。

▼全件表示